FR14C0016I2 - Vacccin west nile - Google Patents

Vacccin west nile

Info

Publication number
FR14C0016I2
FR14C0016I2 FR14C0016C FR14C0016C FR14C0016I2 FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2 FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2
Authority
FR
France
Prior art keywords
west nile
nile vaccine
vaccine
west
nile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0016C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis W LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W LLC filed Critical Zoetis W LLC
Publication of FR14C0016I1 publication Critical patent/FR14C0016I1/fr
Application granted granted Critical
Publication of FR14C0016I2 publication Critical patent/FR14C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR14C0016C 2001-07-27 2014-02-21 Vacccin west nile Active FR14C0016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
FR14C0016I1 FR14C0016I1 (cg-RX-API-DMAC10.html) 2014-03-28
FR14C0016I2 true FR14C0016I2 (fr) 2015-07-24

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0016C Active FR14C0016I2 (fr) 2001-07-27 2014-02-21 Vacccin west nile

Country Status (24)

Country Link
US (8) US7153513B2 (cg-RX-API-DMAC10.html)
EP (3) EP2283858A3 (cg-RX-API-DMAC10.html)
JP (2) JP4718778B2 (cg-RX-API-DMAC10.html)
KR (2) KR20090053967A (cg-RX-API-DMAC10.html)
CN (2) CN1273189C (cg-RX-API-DMAC10.html)
AU (1) AU2002365244B2 (cg-RX-API-DMAC10.html)
BE (1) BE2014C006I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0211492B1 (cg-RX-API-DMAC10.html)
CA (1) CA2452545C (cg-RX-API-DMAC10.html)
CY (1) CY2014010I2 (cg-RX-API-DMAC10.html)
DK (1) DK1427444T3 (cg-RX-API-DMAC10.html)
ES (1) ES2435095T3 (cg-RX-API-DMAC10.html)
FR (1) FR14C0016I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20040195B1 (cg-RX-API-DMAC10.html)
HU (2) HU228690B1 (cg-RX-API-DMAC10.html)
LU (1) LU92348I2 (cg-RX-API-DMAC10.html)
ME (1) ME00491B (cg-RX-API-DMAC10.html)
MX (1) MXPA04000680A (cg-RX-API-DMAC10.html)
NZ (3) NZ570270A (cg-RX-API-DMAC10.html)
PL (2) PL220846B1 (cg-RX-API-DMAC10.html)
PT (1) PT1427444E (cg-RX-API-DMAC10.html)
RS (1) RS53184B (cg-RX-API-DMAC10.html)
WO (1) WO2003061555A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200401596B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
PT1427444E (pt) * 2001-07-27 2013-11-19 Zoetis W Llc Vacina contra o vírus do nilo ocidental
EP1664786B1 (en) * 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
CA2601705A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
US8048429B2 (en) 2005-06-24 2011-11-01 Intervet International B.V. Inactivated chimeric flavivirus
BRPI0617735B1 (pt) * 2005-10-19 2022-05-17 University Of Florida Research Foundation Inc Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
WO2007094854A2 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
CN101460519B (zh) 2006-06-06 2013-06-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
CN101883581A (zh) 2007-11-06 2010-11-10 惠氏有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9642908B2 (en) * 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
CN102348466B (zh) * 2008-08-29 2014-05-07 贝林格尔.英格海姆维特梅迪卡有限公司 西尼罗病毒疫苗
BR112012008185A2 (pt) * 2009-10-07 2016-08-16 Wyeth Llc composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
BR122019023542B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Vetmedica, Inc Composição imunogênica compreendendo uma ou mais cepas de vírus da rinite equina b (erbv) inativado e seu método de preparação
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
JP6505084B2 (ja) * 2013-05-14 2019-04-24 ゾエティス・サービシーズ・エルエルシー 免疫刺激性オリゴヌクレオチドを含む新規のワクチン組成物
MX2016002903A (es) * 2013-09-05 2016-06-06 Zoetis Services Llc Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
MX2021010343A (es) 2019-02-27 2022-01-18 Univ Rochester Vacuna para la influenza multivalente con virus vivo atenuado para la prevencion y el control del virus de la influenza equina (eiv) en caballos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
NZ285324A (en) * 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP4472250B2 (ja) * 2000-10-04 2010-06-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 高発現可能遺伝子
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
EP1372711A4 (en) * 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
PT1427444E (pt) * 2001-07-27 2013-11-19 Zoetis W Llc Vacina contra o vírus do nilo ocidental
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens

Also Published As

Publication number Publication date
EP2283858A2 (en) 2011-02-16
US7153513B2 (en) 2006-12-26
WO2003061555A3 (en) 2004-04-15
PL368535A1 (en) 2005-04-04
PL398575A1 (pl) 2012-06-18
US20030091595A1 (en) 2003-05-15
JP4718778B2 (ja) 2011-07-06
MXPA04000680A (es) 2004-04-05
BRPI0211492B1 (pt) 2016-06-21
CN1935258B (zh) 2013-04-03
US20070231350A1 (en) 2007-10-04
HK1066470A1 (en) 2005-03-24
PL212212B1 (pl) 2012-08-31
FR14C0016I1 (cg-RX-API-DMAC10.html) 2014-03-28
HUP0401606A3 (en) 2005-02-28
JP2005515236A (ja) 2005-05-26
CY2014010I2 (el) 2024-02-16
US20070166802A1 (en) 2007-07-19
US7648705B2 (en) 2010-01-19
NZ531265A (en) 2008-08-29
PL220846B1 (pl) 2016-01-29
US7445787B2 (en) 2008-11-04
YU8004A (sh) 2006-08-17
ES2435095T3 (es) 2013-12-18
PT1427444E (pt) 2013-11-19
DK1427444T3 (da) 2013-11-04
KR20090053967A (ko) 2009-05-28
CA2452545C (en) 2015-06-09
NZ570270A (en) 2010-08-27
ZA200401596B (en) 2005-07-27
ME00491B (me) 2011-10-10
WO2003061555A2 (en) 2003-07-31
CN1935258A (zh) 2007-03-28
US20070231349A1 (en) 2007-10-04
US20070166325A1 (en) 2007-07-19
KR20040028952A (ko) 2004-04-03
US20070166326A1 (en) 2007-07-19
CY2014010I1 (el) 2020-05-29
HRP20040195B1 (hr) 2014-07-18
CA2452545A1 (en) 2003-07-31
EP1427444A4 (en) 2008-01-02
RS53184B (sr) 2014-06-30
HRP20040195A2 (en) 2004-08-31
AU2002365244B2 (en) 2007-12-06
LU92348I9 (cg-RX-API-DMAC10.html) 2019-01-02
JP2011057692A (ja) 2011-03-24
HUP0401606A2 (hu) 2004-11-29
EP2281572A1 (en) 2011-02-09
HU228690B1 (en) 2013-05-28
US20070178119A1 (en) 2007-08-02
LU92348I2 (fr) 2014-09-22
EP2283858A3 (en) 2011-03-23
CN1273189C (zh) 2006-09-06
BR0211492A (pt) 2004-08-17
CN1535157A (zh) 2004-10-06
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
HUS1300055I1 (hu) 2016-08-29
NZ553165A (en) 2008-09-26
US20070166324A1 (en) 2007-07-19
BE2014C006I2 (cg-RX-API-DMAC10.html) 2021-02-04
US7648706B2 (en) 2010-01-19

Similar Documents

Publication Publication Date Title
FR14C0016I2 (fr) Vacccin west nile
DK1390066T3 (da) Vaccinesammensætning
LU93048I2 (fr) Proteq west nile
NO20031483L (no) Vaksine
PL363005A1 (pl) Szczepionki
DE60230760D1 (de) Grippe-impfstoffzusammensetzung
NO20034683D0 (no) Intradermal vaksineinnretning
NO20024172D0 (no) Vaksine
DE60239828D1 (de) Ür
IS7291A (is) Merkt kirni
NO20026175L (no) Vaksinesammensetning
IS7297A (is) Streptococcis Pneumoniae bóluefni
NO20031705L (no) Vaksiner
IS7547A (is) Ónæmisvaldandi samsetningar
NO20033882D0 (no) Vaksine
EP1423141A4 (en) VACCINE
IS7831A (is) Bóluefni
DE60328408D1 (de) Impfstoff
NO20034165D0 (no) Forankringshylse
NO20051561D0 (no) Vaksine
DE10290185D2 (de) Tumorvakzine
SE0100410D0 (sv) Hållaranordning
SE0103470D0 (sv) Hållaranordning
SE0103415D0 (sv) Hållaranordning
FI5103U1 (fi) Salibandymaila